Summary

The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in February 2010 and introduced on the Navajo and White Mountain Apache reservations in March/April 2010. The primary objective of this study is to measure the direct and indirect impact of PCV13 on pneumococcal disease and nasopharyngeal colonization among both vaccinated and unvaccinated persons. Secondary objectives include evaluating vaccine immunogenicity, the pace of vaccine uptake into the community, and the risk of coinfection by respiratory viruses and pneumococcus.